KELIX bio

Dubai, United Arab Emirates Founded: 2020 • Age: 6 yrs Acquired By Mubadala
Drug manufacturing for multiple therapeutic areas is pursued through RD.

About KELIX bio

KELIX bio is a Healthcare company based in Dubai (United Arab Emirates) founded in 2020 by Alhadi Alwazir, and was acquired by Mubadala in March 2024. Drug manufacturing for multiple therapeutic areas is pursued through RD. KELIX bio has raised $150 million across 3 funding rounds from investors including Mubadala, DPI and British International Investment. KELIX bio has completed 1 acquisition, including Pharmaceutical Institute. Its focus areas include Diversified Pharmaceuticals.

Company details

KELIX bio was established in 2020 and is headquartered in Dubai, United Arab Emirates. Research and development efforts are directed toward the production of pharmaceuticals across various therapeutic domains. Operations in the biotechnology sector emphasize drug manufacturing processes. The company was co-founded by Alhadi Alwazir, with activities centered on advancing therapeutic solutions in this field.

  • Headquarters Dubai, United Arab Emirates
  • Founders Alhadi Alwazir
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website kelixbio.com
  • Social LinkedIn
  • Acquired by Mubadala (Mar 2024)
Key Metrics

Funding Insights of KELIX bio

KELIX bio has successfully raised a total of $150M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $150M
  • Total Rounds 3
  • First Round $100M

    (Jun 2020)

  • Investors Count 2

All 3 funding rounds of KELIX bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Oct 2022Series D–Development Partners International
–
Jan 2022$50MSeries C––
Jun 2020$100MSeries C––
Valuation history

3 investors in total: 3 institutional.

Investors in KELIX bio

KELIX bio has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Mubadala, DPI and British International Investment.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
A premier African investment firm focused on high-growth businesses.
2007dpi-llp.comLondon, United Kingdom
bii.co.uk
Sovereign wealth fund of United Arab Emirates
2002mubadala.comAbu Dhabi, United Arab Emirates
Premium access

Investor details for KELIX bio

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of KELIX bio

1 people are tracked at KELIX bio (1 in leadership).

NameRoleGroup
Alhadi Alwazir
Co-FounderLeadership
Premium access

Complete people profiles for KELIX bio

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by KELIX bio

KELIX bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Pharmaceutical Institute.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Pharmaceutical Institute is engaged in producing generic medicines in Morocco.
phi.maRabat, Morocco1988Mar 2022β€’β€’β€’β€’
Premium access

Complete acquisition details for KELIX bio

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of KELIX bio

5 dated milestones of KELIX bio across 4 years, from founding to its latest funding, stage changes and deals.

  1. Founded KELIX bio is founded.
  2. Funding First funding round of $100.0M.
  3. Acquisition Acquires Pharmaceutical Institute.
  4. Funding Latest funding round, Series D,.
  5. Exit Acquired by Mubadala.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Kelix Bio

Premium access

Complete news archive for KELIX bio

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about KELIX bio

KELIX bio was founded in 2020.

KELIX bio is headquartered in Dubai, United Arab Emirates. It is registered at Dubai, Dubai, United Arab Emirates.

KELIX bio is a funded company, having raised a total of $150M across 3 funding rounds to date. The company's 1st funding round was a Series C of $100M, raised on Jun 2020.

KELIX bio was established in 2020 and is headquartered in Dubai, United Arab Emirates. Research and development efforts are directed toward the production of pharmaceuticals across various therapeutic domains. Operations in the biotechnology sector emphasize drug manufacturing processes. The company was co-founded by Alhadi Alwazir, with activities centered on advancing therapeutic solutions in this field.

KELIX bio has made 1 acquisition, including Pharmaceutical Institute.

KELIX bio has 3 investors. Key investors include Mubadala, DPI, and British International Investment.

Yes. KELIX bio was acquired by Mubadala in March 2024.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available